AsherBio Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$55M
- Investors
-
17
AsherBio General Information
Description
Operator of a biotechnology firm intended to offer precisely targeted immunotherapies to overcome the clinical limitations of immune-based therapies. The company's immunotherapies selectively activate only the immune cell types that drive the desired therapeutic response, offering effective and tolerable treatment for patients, enabling healthcare professionals to preferentially activate the desired immune cell types while minimizing the activation of others.
Contact Information
Website
www.asherbio.comCorporate Office
- 650 Gateway Boulevard
- Suite 100
- South San Francisco, CA 94080
- United States
Corporate Office
- 650 Gateway Boulevard
- Suite 100
- South San Francisco, CA 94080
- United States
AsherBio Timeline
AsherBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series C) | 16-Apr-2024 | $55M | Completed | Clinical Trials - Phase 1 | ||
| 5. Debt - General | 15-Nov-2023 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series B) | 01-Sep-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 23-Mar-2021 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | 05-Sep-2019 | $490K | $640K | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | 21-Aug-2019 | $150K | $150K | Completed | Clinical Trials - Phase 1 |
AsherBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 362,500 | $0.000010 | $0.8 | $0.8 | 1x | $0.8 | 0.19% | |
| Seed-1 | 1,050,000 | $0.000010 | $0.14 | $0.14 | 1x | $0.14 | 0.55% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
AsherBio Comparisons
Industry
Financing
Details
AsherBio Competitors (56)
One of AsherBio’s 56 competitors is Accent Therapeutics, a Venture Capital-Backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Accent Therapeutics | Venture Capital-Backed | Lexington, MA | ||||
| MaveriX Oncology | Venture Capital-Backed | Palo Alto, CA | ||||
| Alpha-9 Oncology | Venture Capital-Backed | Vancouver, Canada | ||||
| PIPr Therapeutics | Venture Capital-Backed | Durham, NC | ||||
| Synthekine | Venture Capital-Backed | Menlo Park, CA |
AsherBio Patents
AsherBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4680645-A1 | Fusion protein and uses thereof | Inactive | 17-Mar-2023 | ||
| WO-2024196798-A1 | Fusion protein and uses thereof | Inactive | 17-Mar-2023 | ||
| AU-2023353978-A1 | Fusions with cd8 antigen binding molecules for treating chronic viral infection | Pending | 29-Sep-2022 | ||
| EP-4594361-A2 | Fusions with cd8 antigen binding molecules for treating chronic viral infection | Pending | 29-Sep-2022 | ||
| EP-4594361-A4 | Fusions with cd8 antigen binding molecules for treating chronic viral infection | Pending | 29-Sep-2022 | C07K14/52 |
AsherBio Signals
AsherBio Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AstraZeneca | Corporation | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| SNR | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Emles Venture Partners | Venture Capital | Minority |
AsherBio FAQs
-
When was AsherBio founded?
AsherBio was founded in 2019.
-
Where is AsherBio headquartered?
AsherBio is headquartered in South San Francisco, CA.
-
What is the size of AsherBio?
AsherBio has 22 total employees.
-
What industry is AsherBio in?
AsherBio’s primary industry is Drug Discovery.
-
Is AsherBio a private or public company?
AsherBio is a Private company.
-
What is the current valuation of AsherBio?
The current valuation of AsherBio is .
-
What is AsherBio’s current revenue?
The current revenue for AsherBio is .
-
How much funding has AsherBio raised over time?
AsherBio has raised $219M.
-
Who are AsherBio’s investors?
AstraZeneca, Bristol-Myers Squibb, SNR, Alexandria Venture Investments, and Emles Venture Partners are 5 of 17 investors who have invested in AsherBio.
-
Who are AsherBio’s competitors?
Accent Therapeutics, MaveriX Oncology, Alpha-9 Oncology, PIPr Therapeutics, and Synthekine are some of the 56 competitors of AsherBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process